Table 2.
Rank | Name | PSα |
---|---|---|
1 | 5-hydroxytryptamine receptor 2B (r) | 444 |
2 | 5-hydroxytryptamine receptor 2C (r) | 443 |
3 | D(2) dopamine receptor (r) | 436 |
4 | 5-hydroxytryptamine receptor 1A (r) | 409 |
5 | Potassium voltage-gated channel subfamily H member 2 (h) | 406 |
6 | Sodium-dependent serotonin transporter (r) | 394 |
7 = | D(3) dopamine receptor (r) | 385 |
7 = | D(3) dopamine receptor (h) | 385 |
9 | Muscarinic acetylcholine receptor M5 (r) | 379 |
10 | Alpha-1D adrenergic receptor (r) | 376 |
11 | Alpha-1A adrenergic receptor (r) | 371 |
12 | Alpha-1B adrenergic receptor (r) | 369 |
13 | 5-hydroxytryptamine receptor 2A (r) | 367 |
14 = | Sodium-dependent serotonin transporter (h) | 357 |
14 = | 5-hydroxytryptamine receptor 1B (r) | 357 |
16 = | Transporter (r) | 350 |
16 = | Muscarinic acetylcholine receptor M1 (r) | 350 |
18 | Sodium-dependent dopamine transporter (r) | 349 |
19 | Sigma 1-type opioid receptor (h) | 348 |
20 | Sodium channel protein type 2 subunit alpha (h) | 347 |
List of the top 20 targets ranked by their PSα scores across all 182 compounds over the ten models derived from the ten different partitions of the ChEMBL dataset. A higher PSα score suggests that more phospholipidosis positive than negative compounds are associated with the target. A large number of the highly placed targets in our PSα rankings are the intended drug targets of CADs. Each of the top 20 targets comes from either human (h) or rat (r). Tied ranks are denoted by =.